LI 412

Drug Profile

LI 412

Alternative Names: BIO412; Dermatitis therapies - Enhance Biotech; Itch therapies - Enhance Biotech; LI 412 family; LIF 412; Urticaria therapies - Enhance Biotech

Latest Information Update: 22 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enhance Lifesciences
  • Class
  • Mechanism of Action Histamine receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atopic dermatitis; Contact dermatitis; Urticaria

Most Recent Events

  • 21 Apr 2004 Phase-II clinical trials in Atopic dermatitis in USA (Topical)
  • 21 Apr 2004 Phase-II clinical trials in Contact dermatitis in USA (Topical)
  • 21 Apr 2004 Phase-II clinical trials in Urticaria in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top